½ÃÀ庸°í¼­
»óǰÄÚµå
1424378

¼¼°èÀÇ ´ÏÄÚÆ¾ ´ëü¿ä¹ý ½ÃÀå : Á¦Ç° À¯Çüº°, À¯Åë ä³Îº°, Áö¿ªº°

Global Nicotine Replacement Therapy Market, By Product Type, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ´ÏÄÚÆ¾ ´ëü¿ä¹ý ½ÃÀå ±Ô¸ð´Â 2023³â 534¾ï 7,000¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 1,053¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß CAGRÀº 10.2%ÀÔ´Ï´Ù.

µµÇ¥ 1. ¼¼°èÀÇ ´ÏÄÚÆ¾ ´ëü¿ä¹ý ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2023³â.

https://www.coherentmarketinsights.com/images/research-methodology/196846global-nicotine-replacement-therapy-market-figure-1.png

´ÏÄÚÆ¾ ´ëü¿ä¹ý(NRT)¿¡´Â ÆÐÄ¡, ²­, Æ®·ÎÄ¡, ÈíÀÔ±â, Á¡ºñÁ¦ µî ±Ý¿¬ ¹× ±âŸ ´ã¹è Á¦Ç°ÀÇ ±Ý¿¬À» ½ÃµµÇÏ´Â »ç¶÷µéÀÇ ´ÏÄÚÆ¾ ¼·Ãë·®À» ÁÙÀÌ´Â ´Ù¾çÇÑ Á¦Ç°ÀÌ Æ÷ÇԵ˴ϴÙ. Áö³­ ¼ö½Ê ³â µ¿¾È °úÇÐÀû Á¶»ç´Â Èí¿¬ °Ç°­¿¡ ´ëÇÑ À§ÇèÀ» ´õ Àß ¾Ë°Ô µÇ¾úÀ¸¸ç ±Ý¿¬¿¡ ÀÇ¿åÀ» °¡Áø Èí¿¬ÀÚ°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. NRT´Â ½Ã°£ÀÌ Áö³²¿¡ µû¶ó Á¡Â÷ ´ÏÄÚÆ¾À» ¹æÃâÇÏ°í ´ã¹è ¿¬±â¿¡ Æ÷ÇÔµÈ À¯ÇØÇÑ µ¶¼Ò¸¦ ¼·ÃëÇÏÁö ¾Ê°í ±Ý¿¬ Ãʱ⠿å¸Á°ú ±Ý´Ü Áõ»óÀ» ¿ÏÈ­½ÃŰ´Â È¿°ú°¡ ÀÖÀ½ÀÌ ÀÔÁõµÇ¾ú½À´Ï´Ù. Èí¿¬ÀÚ°¡ ±Ý¿¬Çϱâ À§Çؼ­´Â ÀÇÁöÀÇ Èû¸¸À» ÅëÇÑ ¹æ¹ýÀÌ ¿©ÀüÈ÷ ÁÖ·ùÀÌÁö¸¸, NRT´Â Áõ°Å¿¡ ±â¹ÝÇÑ »õ·Î¿î ¿É¼ÇÀ» Á¦°øÇÏ°í ¼ö¹é¸¸ ¸íÀÇ »ç¶÷µéÀÌ ±Ý¿¬À¸·Î°¡´Â ±æÀ» °È´Â µ¥ µµ¿òÀ̵˴ϴÙ.

½ÃÀå ¿ªÇÐ:

¼¼°èÀÇ ´ÏÄÚÆ¾ ´ëü¿ä¹ý ½ÃÀåÀº Èí¿¬ °ü·Ã ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ´ã¹è »ç¿ëÀÇ °Ç°­ À§Çè¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó¿¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀüÀÚ ´ã¹è¿Í °°Àº NRT Á¦Ç°ÀÇ Àú·ÅÇÑ ´ëüǰÀ» »ç¿ëÇÒ ¼ö ÀÖ°ÔµÈ °ÍÀÌ ½ÃÀå ¾ïÁ¦¿äÀÎÀ̱⵵ ÇÕ´Ï´Ù. ½ÃÀå ÁøÀÔ ±â¾÷Àº º¸´Ù Çõ½ÅÀûÀÎ ´ÏÄÚÆ¾ ½ÃÀå °³Ã´ ±â¹ý°ú ´Ù¾çÇÑ ¶óÀÌÇÁ½ºÅ¸ÀÏ¿¡ ´ëÀÀÇÏ´Â NRT º´¿ë ¿ä¹ýÀÇ °³¹ß¿¡ ÅõÀÚÇÒ ±âȸ°¡ ÀÖ½À´Ï´Ù. Èí¿¬ Àα¸°¡ ¸¹°í ÀÇ·áÁ¦µµ°¡ È®´ëµÇ°í ÀÖ´Â ±¹°¡µµ Å« ½ÃÀåÀÇ °¡´É¼ºÀ» Áö´Ï°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 5¿ù 4ÀÏ ¹Ì±¹ Áúº´´ëÃ¥ ¿¹¹æ¼¾ÅͰ¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é 2021³â¿¡´Â ¹Ì±¹ ¼ºÀÎÀÇ ÃßÁ¤ 11.5%(2830¸¸ ¸í)°¡ Èí¿¬Çϰí ÀÖÀ¸¸ç, 2,400¾ï ´Þ·¯ ÀÌ»óÀÇ ÀÇ·á ÁöÃâÀÇ ¼Õ½Ç°ú ¾à 3,720¾ï ´Þ·¯ÀÇ »ý»ê¼ºÀÇ ¼Õ½ÇÀÌ ¹ß»ýÇϰí ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

    • ¼¼°èÀÇ ´ÏÄÚÆ¾ ´ëü¿ä¹ý ½ÃÀåÀ» »ó¼¼ ºÐ¼®Çϰí 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø ±â°£(2023-2030³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
    • ¶ÇÇÑ ´Ù¸¥ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ¼ºÀå ±âȸ¸¦ ¼³¸íÇϰí, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ ¼³¸íÇϰí ÀÖ½À´Ï´Ù.
    • ¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä ÀλçÀÌÆ®µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
    • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±â¹ÝÇÏ¿© ¼¼°èÀÇ ´ÏÄÚÆ¾ ´ëü¿ä¹ý ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù.
    • º» Á¶»ç ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷¿¡´Â Johnson &Johnson Inc.Haleon Group of Companies, Imperial Brands plc, Cipla Inc., Pfizer Inc., GLENMARK PHARMACEUTICALS LTD, Fertin Pharma, Philip Morris Products S.A., British American Tobacco plc, Japan Tobacco Inc., Habitrol., Perrigo Company plc, Die betapharm Arzneimittel GmbH, ITC Limited, Sparsha Pharma International Pvt Ltd, Alkalon A/S µîÀÌ ÀÖ½À´Ï´Ù.
    • ÀÌ ¸®Æ÷Æ®·ÎºÎÅÍ ÀλçÀÌÆ®¿¡ ÀÇÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ ¹× ±â¾÷ÀÇ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° ¹ß¸Å, À¯Çü ¾÷, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤À» ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù.
    • ¼¼°èÀÇ ´ÏÄÚÆ¾ ´ëü¿ä¹ý ½ÃÀå ¸®Æ÷Æ®´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü¿©¾÷ü, À繫 ¾Ö³Î¸®½ºÆ® µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¿¡°Ô ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
    • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ ´ÏÄÚÆ¾ ´ëü¿ä¹ý ½ÃÀåÀÇ ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå °³¿ä

  • ¸®Æ÷Æ® ¼³¸í
  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • ½ÃÀå Á¶»ç °á°ú TOP 3
  • TOP 3 ½ÃÀå ±âȸ

Á¦3Àå ÁÖ¿ä ¾÷°è ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¿µÇ⠺м®
  • PEST ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • ±â¼úÀÇ Áøº¸
  • ÇÕº´, Àμö, Çù¾÷ ½Ã³ª¸®¿À
  • ÃÖ±Ù Á¦Ç° ½ÂÀÎ/¹ß¸Å
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®

Á¦4Àå ´ÏÄÚÆ¾ ´ëü ¿ä¹ý ½ÃÀå, Á¦Ç° À¯Çüº°, 2018-2030³â(¹Ì±¹ ¾ï ´Þ·¯)

  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ºÎ¹® µ¿Çâ
  • ÈíÀÔ±â, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ²­, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • °æÇÇ ÆÐÄ¡, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼³ÇÏÁ¤
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ·ÎÁ¨Áö
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ±âŸ
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)

Á¦5Àå ´ÏÄÚÆ¾ ´ëü ¿ä¹ý ½ÃÀå, À¯Åë ä³Îº°, 2018-2030³â(¹Ì±¹ ¾ï ´Þ·¯)

  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ¿Â¶óÀÎ, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ¿ÀÇÁ¶óÀÎ, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)

Á¦6Àå ´ÏÄÚÆ¾ ´ëü ¿ä¹ý ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2018-2030³â(¹Ì±¹ ¾ï ´Þ·¯)

  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ºÎ¹® µ¿Çâ
  • º´¿ø, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • Àü¹® Ŭ¸®´Ð, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ±âŸ, 2018-2030³â(10¾ï ´Þ·¯)
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)

Á¦7Àå ´ÏÄÚÆ¾ ´ëü ¿ä¹ý ½ÃÀå, Áö¿ªº°, 2018-2030³â(¹Ì±¹ ¾ï ´Þ·¯)

  • ¼­·Ð
  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2018-2030³â(10¾ï ´Þ·¯)
  • ºÎ¹® µ¿Çâ
  • Áö¿ªº°
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, 2018-2030³â(10¾ï ´Þ·¯)
  • ºÏ¹Ì
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Á¦Ç° À¯Çüº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, À¯Åë ä³Îº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ±¹°¡º°, 2018-2030³â(10¾ï ´Þ·¯)
  • ¹Ì±¹
  • ij³ª´Ù
  • À¯·´
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Á¦Ç° À¯Çüº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, À¯Åë ä³Îº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ±¹°¡º°, 2018-2030³â(10¾ï ´Þ·¯)
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Á¦Ç° À¯Çüº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, À¯Åë ä³Îº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ±¹°¡º°, 2018-2030³â(10¾ï ´Þ·¯)
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • È£ÁÖ
  • Çѱ¹
  • ASEAN ±¹°¡
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Á¦Ç° À¯Çüº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, À¯Åë ä³Îº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ±¹°¡º°, 2018-2030³â(10¾ï ´Þ·¯)
  • GCC ±¹°¡
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ¼­·Ð
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, Á¦Ç° À¯Çüº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, À¯Åë ä³Îº°, 2018-2030³â(10¾ï ´Þ·¯)
  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ±¹°¡º°, 2018-2030³â(10¾ï ´Þ·¯)
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª

Á¦8Àå ±â¾÷ °³¿ä - ´ÏÄÚÆ¾ ´ëü ¿ä¹ý ½ÃÀå

  • Johnson & Johnson Inc.
  • Haleon Group of Companies
  • Imperial Brands plc
  • Cipla Inc.
  • Pfizer Inc.
  • GLENMARK PHARMACEUTICALS LTD
  • Fertin Pharma
  • Philip Morris Products S.A.
  • British American Tobacco plc
  • Japan Tobacco Inc.
  • Habitrol
  • Perrigo Company plc
  • Die betapharm Arzneimittel GmbH
  • ITC Limited
  • Sparsha Pharma International Pvt Ltd
  • Alkalon A/S

Á¦9Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

    • Âü°í ¹®Çå
    • Á¶»ç ¹æ¹ý
KSA 24.02.23

The global nicotine replacement therapy market size is expected to reach US$ 105.34 Bn by 2030, from US$ 53.47 Bn in 2023, exhibiting a CAGR of 10.2% during the forecast period.

Nicotine replacement therapy (NRT) includes a variety of products like patches, gums, lozenges, inhalers, and nasal sprays that help taper nicotine intake for those attempting to quit smoking and other tobacco products. As the health risks of smoking have become more well-known in recent decades due to scientific research, more smokers are motivated to quit. NRT products have proven effective as they release nicotine gradually over time to help relieve cravings and withdrawal symptoms during the initial quitting process without many of the harmful toxins found in cigarette smoke. While willpower alone is still the primary method for smokers to quit, NRT provides an additional evidence-based option that has helped millions of people on their journey toward becoming smoke-free.

Market Dynamics:

The global nicotine replacement therapy market is driven by the rising prevalence of smoking-related diseases and growing awareness about the health risks of tobacco use. However, the market also faces some restraints from the availability of cheaper alternatives to NRT products like e-cigarettes. There is an opportunity for market players to invest in developing more innovative nicotine delivery methods and combination NRT therapies for different lifestyles. Countries with large smoking populations and expanding healthcare systems also present significant market potential. For instance, on May 4, 2023, according to a report published by the Centers for Disease Control and Prevention, in 2021, an estimated 11.5% (28.3 million) of the U.S. adults smoked cigarettes, due to which there was more than US$ 240 billion loss in healthcare spending and nearly US$ 372 billion productivity was lost.

Key Features of the Study:

    • This report provides an in-depth analysis of the global nicotine replacement therapy market and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
    • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
    • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
    • It profiles key players in the global nicotine replacement therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
    • The key companies covered as a part of this study include Johnson & Johnson Inc. , Haleon Group of Companies, Imperial Brands plc, Cipla Inc., Pfizer Inc., GLENMARK PHARMACEUTICALS LTD, Fertin Pharma, Philip Morris Products S.A., British American Tobacco plc, Japan Tobacco Inc., Habitrol., Perrigo Company plc, Die betapharm Arzneimittel GmbH, ITC Limited , Sparsha Pharma International Pvt Ltd, and Alkalon A/S
    • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
    • The global nicotine replacement therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
    • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nicotine replacement therapy market

Detailed Segmentation:

    • Global Nicotine Replacement Therapy Market, By Product Type
    • Inhalers
    • Gum
    • Transdermal Patches
    • Sublingual Tablets
    • Lozenges
    • Others
    • Global Nicotine Replacement Therapy Market, By Distribution Channel
    • Online
    • Offline
    • Global Nicotine Replacement Therapy Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
    • Global Nicotine Replacement Therapy Market, Key Players
    • Johnson & Johnson Inc.
    • Haleon Group of Companies
    • Imperial Brands plc
    • Cipla Inc.
    • Pfizer Inc.
    • GLENMARK PHARMACEUTICALS LTD
    • Fertin Pharma
    • Philip Morris Products S.A.
    • British American Tobacco plc
    • Japan Tobacco Inc.
    • Perrigo Company plc
    • Die betapharm Arzneimittel GmbH
    • ITC Limited
    • Sparsha Pharma International Pvt Ltd
    • Alkalon A/S

Table of Content

1. Research Objectives and Assumptions

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Overview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Top 3 Market Findings
    • Top 3 Market Opportunity

3. Key Industry Insights

    • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
    • Impact Analysis
    • Pest Analysis
    • Porters Analysis
    • Technological Advancement
    • Merger, Acquisition and Collaboration Scenario
    • Recent Product Approvals/Launches
    • Company Market Share Analysis

4. Nicotine Replacement Therapy Market, By Product Type, 2018 - 2030 ( US$ Billion)

    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Segment Trends
    • Inhalers, 2018 - 2030( US$ Billion)
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Gum, 2018 - 2030( US$ Billion)
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Transdermal Patches, 2018 - 2030( US$ Billion)
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Sublingual Tablets
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Lozenges
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Others
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)

5. Nicotine Replacement Therapy Market, By Distribution Channel, 2018 - 2030 ( US$ Billion)

    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Online, 2018 - 2030( US$ Billion)
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Offline, 2018 - 2030( US$ Billion)
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)

6. Nicotine Replacement Therapy Market, By End User, 2018 - 2030 ( US$ Billion)

    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Segment Trends
    • Hospitals, 2018 - 2030( US$ Billion)
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Ambulatory Surgical Centers, 2018 - 2030( US$ Billion)
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Specialty Clinics, 2018 - 2030( US$ Billion)
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • Others, 2018 - 2030( US$ Billion)
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)

7. Nicotine Replacement Therapy Market, By Region, 2018 - 2030 ( US$ Billion)

    • Introduction
    • Market Share Analysis, 2018 - 2030, ( US$ Billion)
    • Segment Trends
    • By Region
    • Introduction
    • Market Size and Forecast, 2018 - 2030, ( US$ Billion)
    • North America
    • Introduction
    • Market Size and Forecast, By Product Type, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Country, 2018 - 2030, ( US$ Billion)
    • U.S.
    • Canada
    • Europe
    • Introduction
    • Market Size and Forecast, By Product Type, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Country, 2018 - 2030, ( US$ Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest Of Europe
    • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Product Type, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Country, 2018 - 2030, ( US$ Billion)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Asean
    • Rest Of Asia Pacific
    • Middle East & Africa
    • Introduction
    • Market Size and Forecast, By Product Type, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Country, 2018 - 2030, ( US$ Billion)
    • GCC
    • Israel
    • Rest Of Middle East
    • Latin America
    • Introduction
    • Market Size and Forecast, By Product Type, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2030, ( US$ Billion)
    • Market Size and Forecast, By Country, 2018 - 2030, ( US$ Billion)
    • Brazil
    • Mexico
    • Argentina

8. Company Profiles - Nicotine Replacement Therapy Market

    • Johnson & Johnson Inc. *
    • Company Overview
    • Product/Service Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategic Overview
    • Haleon Group of Companies
    • Imperial Brands plc
    • Cipla Inc.
    • Pfizer Inc.
    • GLENMARK PHARMACEUTICALS LTD
    • Fertin Pharma
    • Philip Morris Products S.A.
    • British American Tobacco plc
    • Japan Tobacco Inc.
    • Habitrol.
    • Perrigo Company plc
    • Die betapharm Arzneimittel GmbH
    • ITC Limited
    • Sparsha Pharma International Pvt Ltd
    • Alkalon A/S

9. References and Research Methodology

    • References
    • Research Methodology
    • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦